Navigation Links
VisEn Announces New ProSense® 750 FAST and Neutrophil Elastase™ 680 FAST Fluorescence Molecular Imaging Agents at European Molecular Imaging Meeting 2010

BEDFORD, Mass. and WARSAW, Poland, May 26 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced the commercial launch of two new imaging agents -- ProSense® 750 FAST for expanded versatility in imaging cathepsin activity, and Neutrophil Elastase™ 680 FAST, for imaging of inflammatory elastase activity associated with disease progression and therapeutic response.  The launch announcements were made at the European Molecular Imaging Meeting (EMIM) 2010 in Warsaw, Poland.  

New Research and Application Areas:

  • Cathepsins are well known biomarkers in a range of diseases, including atherosclerosis, oncology, pulmonary pathologies, and arthritis.  The new ProSense 750 FAST agent, a faster-activating, smaller molecule product complement to VisEn's ProSense imaging agent, is designed to target a broad range of cathepsins (B, K, L, S, and V) in live cell and in vivo imaging studies.  With similar pan-cathepsin readout profiles but different activation kinetics and imaging time points, VisEn's ProSense and ProSense FAST enable broader study design choices in imaging these key protease families in disease progression and therapeutic response.
  • Neutrophil elastase is a key protease involved in acute lung injury, acute respiratory distress syndrome, as well as many other inflammatory processes such as emphysema, cystic fibrosis, COPD, wound healing, rheumatoid arthritis, and ischemia-reperfusion.  Neutrophil Elastase 680 FAST is a selective neutrophil elastase-activatable agent designed for imaging of this serine protease both in vitro and in vivo.

"We continue to be very pleased with the expanding capability and rapid adoption of our fluorescence agents and FMT™ imaging systems in imaging and measuring key biologic pathways and biomarkers in research today," said Kirtland Poss, President and CEO of VisEn. "The new ProSense 750 FAST and Neutrophil Elastase 680 FAST imaging agents are two strong new additions to our suite of agents, and we are especially pleased to be able to announce these products along with our many collaborators at the European Molecular Imaging meeting."

VisEn's proprietary fluorescence imaging agents and labels are designed to provide the industry's broadest and most robust range of biologically-specific imaging readouts.  VisEn offers over 35 different fluorescence molecular agents for imaging key disease-associated biologic targets, processes and pathways.  VisEn agent brands include ProSense®, IntegriSense™, AngioSense™, OsteoSense®, MMPSense™, GastroSense™, ReninSense™, Annexin-Vivo™, and the FAST™ line of imaging agents.  VisEn also offers specialized lines of agent labeling dyes, including its proprietary VivoTag® fluorescence labels and its NanoSpark® nanoparticles for customized fluorescence agent conjugation and development.  They are all designed and optimized specifically for superior biocompatibility, brightness, stability and performance in biological imaging applications including in vitro, cell, tissue and in vivo imaging applications.  

All VisEn agents and labels are designed for in vivo biomarker quantification using VisEn's Fluorescence Molecular Tomography (FMT™) imaging systems, or for general use along with other non-quantitative fluorescence in vivo imaging systems.  VisEn agents are also designed to enable complementary in vitro biomarker readouts in cells and tissues using standard fluorescence microscopy and other cellular-based imaging systems.  With a focus on translational research and results, all of VisEn's technologies are designed to generate translational data linking preclinical research into clinical medicine.

About VisEn Medical Inc.

VisEn's in vivo fluorescence imaging technologies, including its Red Fluorescence Agent Portfolio and its Fluorescence Molecular Tomography (FMT) Imaging Systems, provide robust fluorescence molecular imaging performance in identifying, characterizing and quantifying ranges of disease biomarkers and therapeutic efficacy.  VisEn's FMT systems and agents are used by leading research institutions and pharmaceutical companies worldwide in applications including oncology, arthritis, cardiovascular disease, skeletal disorders, and pulmonary disease.  The Company also works with large pharmaceutical and clinical partners to design ranges of tailored molecular imaging agents and applications designed for their specific preclinical and clinical research areas. Additional information can be found at

SOURCE VisEn Medical Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VisEn Launches New VivoTag(R) 680 XL Fluorescence Molecular Imaging Label
2. VisEn Acquires Key Fluorescence Agent Intellectual Property Portfolio and Technology Platforms From Bayer Schering Pharma
3. VisEn Launches New Cat B 680 FAST(TM) Fluorescence Molecular Imaging Agent
4. VisEn Launches New OsteoSense(R) 800 and VivoTag(R) 800 Fluorescence Molecular Imaging Agents
5. VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
6. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
7. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
8. AcelRx Announces Positive Phase 2 Results From a Study of ARX-02 Sufentanil NanoTab(TM) Breakthrough Pain Management System in Treating Cancer Breakthrough Pain
9. ProUroCare Medical Announces Filing of Request to Classify the Prostate Mechanical Imager ("PMI") as a Class II Device
10. Applied Precision Announces New Products for Life Sciences Microscopy at the 110th American Society for Microbiology Meeting in San Diego, CA, May 23-26th.
11. Hisamitsu Pharmaceutical Announces Two New FDA Approved Over-The-Counter Pain Relief Patches
Post Your Comments:
(Date:6/23/2016)... INDIANAPOLIS , June 23, 2016 Roche ... received 510(k) clearance for its Elecsys BRAHMS PCT (procalcitonin) ... severe sepsis or septic shock. With this clearance, Roche ... provide a fully integrated solution for sepsis risk assessment ... associated with bacterial infection and PCT levels in blood ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June ... receiving a Lilly Diabetes Tomorrow,s Leaders Scholarship is any ... scholarship winners, announced today online at ... type 1 diabetes stand in the way of academic ... supported the Foundation,s scholarship program since 2012, and continues ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... blind and certified personal trainer is helping to develop a weight loss fitness plan that ... the two major problems leading the fitness industry today:, , All ... They don’t eliminate all the reasons people quit their exercise program , ...
(Date:6/25/2016)... (PRWEB) , ... June 25, 2016 , ... ... health policy issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, ... work on several important health care topics including advance care planning, healthcare costs ...
(Date:6/25/2016)... ... ... temporary closing of Bruton Memorial Library on June 21 due to a possible lice infestation, ... aspect of head lice: the parasite’s ability to live away from a human host, and ... necessary one in the event that lice have simply gotten out of control. , As ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
Breaking Medicine News(10 mins):